OXAZOLVERBUNDKRISTALL

European patent · EP3774745 · In force

Register entry

Publication number
EP3774745
Application number
EP19718465
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 3, 2019
Published
Feb 17, 2021
Granted
May 29, 2024
Protection ends at the latest
Apr 2, 2039
Next annual fee due
Apr 30, 2027
IPC classes
C07D 263/32 (2006.01)
A61K 31/421 (2006.01)
A61P 17/00 (2006.01)
Priority
JP 2018072717 04.04.2018
PCT application
PCT/JP2019/014730 03.04.2019
PCT publication
WO2019/194211 10.10.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2026

    Change

    Published in Swissreg on 01.05.2026

  2. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  3. Apr 9, 2025

    Change

    Published in Swissreg on 09.04.2025

  4. Jun 5, 2024

    Agent entered

    Representative
    Bovard SA, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 05.06.2024

  5. May 29, 2024

    Granted

    Published in Swissreg on 29.05.2024

Parties

Holder

Otsuka Pharmaceutical Co., Ltd.

2-9, Kanda Tsukasa-machi Chiyoda-ku, Tokyo 101-8535, JP

Agent

Bovard AG

Bovard SA

Optingenstrasse 16, 3013 Bern

Inventor

HIROTA, Ryosuke

Osaka-shi, Osaka 540-0021, JP

KANAI, Naohiko

Osaka-shi, Osaka 540-0021, JP

YASUTOMI, Takayuki

Osaka-shi, Osaka 540-0021, JP

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.